Andrew Hill

Andrew Hill graduated from Oxford University, and then completed his PhD at Amsterdam University.  He has worked on the development of antiretrovirals since the early 1990's, including the initial studies of 3TC, abacavir, saquinavir and darunavir.  He is currently a Senior Visiting Research Fellow at the University of Liverpool.  He specialises in treatment access issues for HIV and Hepatitis C in developing countries, and has worked on dose optimisation trials to modify the doses of several antiretrovirals.